Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
Kawaguchi A, Mitsudo K, Nobuyoshi M, Minamino R, Hayasaki K, Nakashima M, Yamamoto A; ATHEROMA Study Group. Kawaguchi A, et al. Among authors: yamamoto a. J Cardiovasc Risk. 2002 Feb;9(1):7-16. doi: 10.1177/174182670200900102. J Cardiovasc Risk. 2002. PMID: 11984212 Clinical Trial.
Risk factors for coronary heart disease in the Japanese--comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervention study.
Yamamoto A, Richie G, Nakamura H, Hosoda S, Nobuyoshi M, Matsuzaki M, Tan CE, Keech A, Mabuchi H, Horibe H, Tenba H; ASPAC study members in Japan; Research Committee on Serum Lipid Survey 1990 Japan. Yamamoto A, et al. J Atheroscler Thromb. 2002;9(4):191-9. doi: 10.5551/jat.9.191. J Atheroscler Thromb. 2002. PMID: 12226551 Free article.
Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.
Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yamagishi M, Miyatake K, Kamikubo Y, Kumeda K, Tsushima M, Yamamoto A, Kato H. Kawaguchi A, et al. Among authors: yamamoto a. Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):251-8. doi: 10.1161/01.atv.20.1.251. Arterioscler Thromb Vasc Biol. 2000. PMID: 10634826
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Yamamoto A, Arakawa K, Sasaki J, Matsuzawa Y, Takemura K, Tsushima M, Fujinami T, Mabuchi H, Itakura H, Yamada N, Toyota T, Oikawa S; Rosuvastatin Dose-Ranging Trialist Group. Yamamoto A, et al. J Atheroscler Thromb. 2002;9(1):48-56. doi: 10.5551/jat.9.48. J Atheroscler Thromb. 2002. PMID: 12238638 Free article. Clinical Trial.
4,440 results